Sexual Health

Introducing Verrutop For Sexual Health

Verrutop has been regularly used in a number of European settings for several years and whilst much of the published clinical data spans all aspects of HPV wart therapy from a dermatological perspective there have been a number of standalone reports looking specifically at ano-genital warts which bolster the specific use of Verrutop in this field.

The most recent study, a single blinded RCT post-dates the publication of the EADV Position document.

Verrutop has an impressive and increasing range of clinical studies to support its introduction.

Sign up for more information on Verrutop

Please Click Here to sign up to our mailing list for more information on Verrutop and other products from Espère Healthcare Ltd


Verrutop: included in recent Position Statement

Treatment: Nitric–zinc complex topical solution

Mode of action: Induces a caustic effect on the wart through mummification and protein denaturation/coagulation action

Schedule: Once or up to four times; repeat at 2-week intervals if needed

Clearance rate (%): 90–99

Recurrence rate (%): Not evaluated

Advantages: Efficacy, Easy application

Disadvantages: Current evidence in AGW available from a limited number of patients only, Investigation of recurrence rate is required

Clinical Papers


Call Us


For more information or to arrange a face to face meeting (or virtual meeting) please call us on 01462 346100 or email

To Order

Verrutop 4x0.1ml ampoule pack can be ordered directly from Espère Healthcare Ltd by calling us on 01462 346100 and we will deliver within 24-48 hours.

Alternatively, Verrutop is listed under the NHS Supply Chain Sexual Health Framework using NPC code FPH053

Verrutop Data

Verrutop – changing the management of genital warts – a little drop at a time